European Commission Study Identifies Novel Actinium 225 Radioimmunoconjugate for Targeted Alpha Therapy of Triple Negative Breast Cancer
October 11, 2026
October 11, 2026
BRUSSELS, Belgium, Oct. 11 (TNSLrpt) -- 225Ac-DOTA-GA-panitumumab: a promising candidate for targeted alpha therapy of triple-negative breast cancer - A publication from the European Commission - Oct. 8, 2026
Here are excerpts:
* * *
Abstract: Triple-negative breast cancer (TNBC) represents one of the most aggressive molecular subtypes, accounting for approximately 10-20% of breast cancer cases. Due to the absence of estrogen receptor (ER), progesterone rec . . .
Here are excerpts:
* * *
Abstract: Triple-negative breast cancer (TNBC) represents one of the most aggressive molecular subtypes, accounting for approximately 10-20% of breast cancer cases. Due to the absence of estrogen receptor (ER), progesterone rec . . .
